Disclosed are small molecules against cereblon to enhance effector T cell function. Methodos of making thes molecules and methods of using them to treat various disease states are also disclosed.

The present invention provides compounds of formula I or II:

##STR00001##

wherein X.sup.1, X.sup.3, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula I, pharmaceutical compositions comprising them and their use as medicaments.

Described herein are cyclic amide-containing pyridyl-xanthines and pharmaceutical compositions thereof that are usesful as antagonists of A.sub.2B adenosine receptors.

Disclosed are compounds having structural formula I, and related pharmaceutical compositions. Also disclosed are therapeutic methods, e.g., of treating diseases such as diabetic kidney disease, diabetic nephropathy, obesity-related kidney disease, focal segmental glomerular sclerosis, IgA nephropathy, nephrotic syndrome, kidney fibrosis, Prader Willi syndrome, metabolic syndrome, gastrointestinal diseases, non-alcoholic liver disease, alcoholic liver disease, or non-alcoholic fatty liver disease, using the compounds of Formula (I).

##STR00001##

Disclosed are compounds having structural formula I, and related pharmaceutical compositions. Also disclosed are therapeutic methods, e.g., of treating diseases such as diabetic kidney disease, diabetic nephropathy, obesity-related kidney disease, focal segmental glomerular sclerosis, IgA nephropathy, nephrotic syndrome, kidney fibrosis, Prader Willi syndrome, metabolic syndrome, gastrointestinal diseases, non-alcoholic liver disease, alcoholic liver disease, or non-alcoholic fatty liver disease, using the compounds of Formula (I).

##STR00001##

Compounds, compositions and methods are described for inhibiting the TRPC5 ion channel and disorders related to TRPC5.

Compounds, compositions and methods are described for inhibiting the TRPC5 ion channel and disorders related to TRPC5.

The present invention relates to dual delta (δ) and gamma (γ) PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of Pi3K kinase mediated diseases or disorders with them.

The present invention relates to dual delta (δ) and gamma (γ) PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of Pi3K kinase mediated diseases or disorders with them.

A compound of formula (I), for use in the treatment of non-traumatic acquired brain injury,

##STR00001## in which M represents a NR.sup.1R.sup.2 group, an OR.sup.1 group or a SR.sup.1 group, A represents a NR.sup.4R.sup.5 group, an OR.sup.10 group or a hydrogen atom, R.sup.3 is a (C.sub.1-C.sub.6)alkyl group, a (C.sub.1-C.sub.6)cycloalkyl group, an aryl group, a —CH.sub.2-aryl group, a CH.sub.2-(C.sub.1-C.sub.6)cycloalkyl group or a —CH.sub.2-heteroaryl group, and its addition salts with pharmaceutically acceptable acids. A compound of formula (I) wherein R.sup.5 is a (C.sub.1-C.sub.8)alkyl group or a (C.sub.1-C.sub.6)cycloalkyl group, said alkyl and cycloalkyl group being substituted with one, two or three —OCOR.sup.a group(s).